Steps Ahead In the Fight Against Viral Hepatitis

Learning more about Viral Hepatitis with Sysmex

Over the last 3 decades, many viral pathogens have emerged to cause epidemics and pandemics. While some viruses have faded into the background, others remain a significant burden of disease and mortality. In Asia Pacific, Hepatitis B and C viruses are highly prevalent compared to the rest of the world. Global efforts to control these viruses have led to extensive HBV vaccination programs and highly effective direct acting anti-viral therapies (DAAs) for HCV. However, healthcare equity remains a challenge for many infected patients across the Asia Pacific region.Chronic hepatitis patients carry risk for developing progressive liver fibrosis that reduce overall liver function, leading to cirrhosis. Cirrhosis decreases the quality of life, can increase the risk of infection with other pathogens, and for a significant proportion of patients, can develop into lethal hepatocellular carcinoma.

With this educational series, Sysmex is deeply honored to have eminent regional clinicians and scientists share their experiences in caring for hepatitis patients in Asia, and we hope that you too will join us to reignite the regional commitment to fight against viral hepatitis.

 Dr. Carlum Shiu

Director, Regional Marketing and Scientific Affairs

Sysmex Asia Pacific

Overview of Chapters